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Abstract
Background: Our study aimed to determine the association between forced expiratory volume in one second
(FEV1) and subsequent fatal and non-fatal events in a general population.
Methods: The Norfolk (UK) based European Prospective Investigation into Cancer (EPIC-Norfolk) recruited 25,639
participants between 1993 and 1997. FEV1 measured by portable spirometry, was categorized into sex-specific
quintiles. Mortality and morbidity from all causes, cardiovascular disease (CVD) and respiratory disease were
collected from 1997 up to 2015. Cox proportional hazard regression analysis was used with adjustment for socio-
economic factors, physical activity and co-morbidities.
Results: Mean age of the population was 58.7 ± 9.3 years, mean FEV1 for men was 294± 74 cL/s and 214± 52 cL/s
for women. The adjusted hazard ratios for all-cause mortality for participants in the highest fifth of the FEV1
category was 0.63 (0.52, 0.76) for men and 0.62 (0.51, 0.76) for women compared to the lowest quintile. Adjusted
HRs for every 70 cL/s increase in FEV1 among men and women were 0.77 (p < 0.001) and 0.68 (p < 0.001) for total
mortality, 0.85 (p<0.001) and 0.77 (p<0.001) for CVD and 0.52 (p <0.001) and 0.42 (p <0.001) for respiratory disease.
Conclusions: Participants with higher FEV1 levels had a lower risk of CVD and all-cause mortality. Measuring the
FEV1 with a portable handheld spirometry measurement may be used as a surrogate marker for cardiovascular risk.
Every effort should be made to identify those with poorer lung function even in the absence of cardiovascular
disease as they are at greater risk of total and CV mortality.
Keywords: FEV1, Cardiovascular, mortality, morbidity, Population-Based, Prospective, Respiratory disease, EPIC-
NORFOLK
Background
It is known that patients with chronic obstructive pul-
monary disease and those with low forced expiratory
volume in 1 second (FEV1) have increased incidence of
cardiovascular disease (CVD) [1, 2] and all-cause
mortality [3, 4]. However, less is known about lung func-
tion and cardiovascular mortality and morbidity in a
normal population, particularly among the non-smokers
and ex-smokers. Although many population based stud-
ies of lung function have adjusted for smoking habits,
body mass index and co-morbidities, few studies have
considered the role of socio-economic factors and phys-
ical inactivity in relation to lung function and total mor-
tality [5]. This study aimed to examine whether FEV1 at
baseline is a risk factor for mortality and morbidity of
cardiovascular and respiratory diseases in a population-
based cohort over an 18-year period.
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Methods
Participants
The study population was based in the Norfolk region,
United Kingdom (UK). A total of 77,630 men and
women aged between 40–79 were selected from age-sex
registers of general practices and were invited by post to
participate in the baseline survey [6]. The participants
were part of the European Prospective Investigation into
Cancer (EPIC) study [6].
Eligibility criteria
1. Adults aged 40-79 years from age-sex registers of
general practices
Exclusion criteria
1. Those who have ischaemic heart disease, stroke or
cancer at baseline.
2. Non-responders to the postal invitation to join the
study.
This large multicentre prospective general population
study was originally designed not only to investigate the
relationship between diet, cancer, and chronic diseases
[7], but it also explores exposures other than diet, and
outcomes other than cancer as part of the larger study
[6]. Out of 30,445 subjects who consented to partici-
pate in the study, 25,639 men and women actually
attended a baseline health check between 1993-1997 [6].
Ethics approval was obtained from the Norfolk Ethics
Committee (Rec Ref: 98CN01) and all participants gave
informed written consent prior to the study.
Data collection
FEV1 measurement
All subjects were instructed by trained nurses to per-
form spirometry measurements using a portable elec-
tronic turbine spirometer (Micro Medical, Rochester,
UK) following a standard protocol. Two measurements
were recorded for each participant and the higher of the
two values for FEV1 was entered for analysis. The repro-
ducibility of FEV1 was 2.2%. A previous study reported
that this device was accurate and comparable to the
Vitalographspirometer [8] and the reproducility of FEV1
differed by only 2.2%. Calibration was performed regu-
larly on a weekly basis to ensure the accuracy and preci-
sion of both equipment and personnel [6]. Only FEV1 is
reported here. Although the handheld spirometry device
measures both FEV1 and forced vital capacity (FVC), the
FVC measures did not add any extra information [9].
Anthropometric, lifestyle and socio-economic measurements
Trained nurses measured participants’ height and weight
with patients wearing light clothing and without shoes.
They used a stadiometer to measure height to the near-
est 0.1 cm, and Salter scale for weight to the nearest 100
g. We computed the Body Mass Index (BMI) as weight
in kilograms per square meter height (kg/m2). Blood
Pressure (BP) was recorded using an Accutorr
non-invasive oscillometric blood pressure monitor
(Datascope Medical, Huntingdon, United Kingdom) after
the participant had been seated for 5 minutes. The mean
of 2 readings was entered for analysis. Non-fasting blood
samples were taken. Plasma concentration of total chol-
esterol was measured with the RA 1000 Technicon ana-
lyser (Bayer Diagnostics, Basingstoke) and the plasma
vitamin C concentration was estimated by using a
fluorometric assay within a week of sampling [10, 11].
For data collection, all participants provided their in-
formation via several self-administered questionnaires.
The questionnaires included sociodemographic data, a
comorbidities section as well as a health and lifestyle
questionnaire (HLQ). The diagnosis of chronic diseases
like diabetes, hypertension, ischaemic heart disease,
stroke, cancer, asthma, and bronchitis were recorded as
present when participants answered “yes” to question
“Has a doctor ever told you that you have any of the fol-
lowing conditions?” Smoking status based on the health
and lifestyle questionnaire was classified as current,
former, or never smokers. Current smokers were defined
as those currently smoking cigarettes, former smoker as
being a smoker previously and non-smokers were those
who never smoked. Alcohol status was based on the esti-
mated total alcohol consumption in a week as reported
in the health and lifestyle questionnaire and categorized
as current drinker, former drinker, or non-drinker [6].
Social class was categorised into 5 groups based on
the Registrar General’s occupation-based classification
scheme. Social class I: professional jobs, social class II:
secretarial and technicians. Social class III: non-manual
and manual skilful workers. Social class IV: partially skil-
ful workers; social class V: unskilful manual workers. We
re-categorised social class into non-manual (social class
I–III non-manual) and manual (social class III manual,
IV, and V) for our analysis [12].
We classified physical activity into four levels (inactive,
moderately inactive, moderately active and active) using
a self-reported physical activity index, validated with
heart-rate monitoring [13]. We reclassified the partici-
pants as physically inactive (level I) or not physically
inactive (level II-IV) [14].
Educational status was classified into four groups:
degree, A-level, O-level, and below O level. O-level is
applied for those participants who had completed their
schooling at the age of 15 years whereas A-level refers to
participants who had completed their schooling at the
age of 17 years. We also reclassified educational level as
“at least O-level” (which consist of those with
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educational achievement of either O-level, A-level or
degree) and “no qualifications” [12]. Non-fasting blood
samples were obtained by venepuncture as previously
described [6].
Outcome
The outcomes of this study are defined as having cardio-
vascular or respiratory events. Cardiovascular events are
defined as fatal or non-fatal myocardial infarction, an-
gina, heart failure and stroke. Respiratory disease events
are defined as fatal and non-fatal asthma, bronchitis and
chronic obstructive pulmonary disease.
Outcome ascertainment
All fatal events occurring between 1993 and 31st January
2015 (an average of 18 years of follow-up) were captured
by the Office for National Statistics, United Kingdom.
Both fatal cardiovascular (myocardial infarction and
stroke) and fatal respiratory disease (bronchitis, emphy-
sema and asthma) were identified for analysis. Non-fatal
cardiovascular and respiratory events up to March 2009
were identified from the data linkage with East Norfolk
Health Authority database using participant’s unique
National Health Service number.
Follow-up
This was part of the 25-year follow up of the EPIC-Norfolk
study. The study was divided into 5 phases. The first phase
was in 1993-1997, second 1998-2000, third 2004-2011,
fourth 2012-2016 and fifth 2016-2018. The follow-up was
done during each phase. There were 25,639 participants in
the initial phase and by fifth phase, the participants were
5696. Blood, urine test and questionnaire were collected
during the follow-up. In this study, the follow-up was
done from 1993 to 2015 in the second, third and fourth
phase in this study. Baseline FEV1 was done and the
vital status of the participants was ascertained at the
fourth follow up.
Statistical analysis
All statistical analyses were performed using the Statis-
tical Package for Social Sciences (SPSS version 22). A
total of 25,639 participants were entered this analysis.
We excluded 596 patients who did not have an FEV1
measurement. Out of the remaining 25,043 subjects, we
further excluded subjects who had a baseline self-report
of myocardial infarction (n=807) or stroke (n=363) or
cancer (n=1410) leaving a total of 22,662 eligible partici-
pants (10,168 men and 12,494 women)
Participants were divided into sex-specific FEV1 quin-
tiles, and subsequent analyses were sex-specific. We
studied the risk factors distributions among men and
women by FEV1 quintiles. Continuous data are de-
scribed using mean and standard deviation when the
distribution was normal; when the data had a skewed
distribution, median and interquartile range (25-75th
percentile) were used. Categorical data are reported as
percentage and differences tested using Chi-square test
or Fisher exact tests.
We used Cox proportional hazards model to deter-
mine the Hazard Ratio (HRs) by quintiles of all-cause
and disease-specific mortality as well as total fatal and
non-fatal incident cardiovascular and respiratory dis-
eases based on FEV1 quintiles after age adjustment in
model 1. This was followed by model 2 with additional
covariables of education level, social class, self-reported
diabetes, respiratory disease, smoking status, alcohol
consumption, physical activity, height, BMI, systolic
blood pressure, plasma vitamin C concentration and
plasma total cholesterol level. We used regression mod-
elling to test for trend.
We also examined HRs in a subgroup analysis strati-
fied by sex and adjusted for age group, BMI, social class,
smoking status, physical activity, plasma vitamin C level
and after the exclusion of those with any history of
respiratory diseases (prevalent bronchitis/ emphysema
and asthma) and those who died < 5 years of follow-up.
Statistical significance is defined as p-value < 0.05. We
also calculated regression coefficients with 95 percent
confidence intervals.
Results
A total of 22,662 participants were entered analysis and
are described in Table 1. There were 44.9% men
(n=10,168). Mean age of men and women was 58.9
years old and 58.5 years old respectively. Mean FEV1
was 294±74 cL/s for men and 214 ± 52 cL/s for women.
Total all-cause mortality events were 5854 over the 18
years. CVD mortality events were 957 (9.4%) for men
and 798 for women (6.4%) and respiratory disease mor-
tality events were 267 in men (2.6%) and 311 in women
(2.5%). There were 3307(32.5%) and 3378(14.5%) total
cardiovascular events and 1391(13.7%) and 1844(14.8%)
respiratory disease events for men and women respect-
ively. Mean baseline FEV1 for men who died was
248cL/s and 310cL/s for men alive at end of follow-up
(p<0.001); 180cL/s for women who died and 223cL/s
for women who were alive (p<0.001) respectively. Mean
baseline age for men who died was 66.3 years and 55.8
years for men alive at end of follow-up; 66.6 years for
women who died and 56.2years for women alive re-
spectively. The baseline FEV1 was lower among the
older participants compared to the younger participants
for both genders, and the baseline FEV1 was also sig-
nificantly lower among those who died prior to the end
of the study compared to those still alive for both male
(p<0.001) and female (p<0.001).
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Comparing the top quintile of FEV1 with the bottom
quintile, FEV1 was approximately one and a half times
higher for both men and women. Men and women in pro-
gressively higher FEV1 quintiles were younger, had lower
systolic blood pressure and anthropometric measures, a
lower prevalence of diabetes, asthma and bronchitis, fewer
current smokers and fewer persons of social class III, IV
and V, a higher education qualification, higher plasma
vitamin C and were more physically active. Overall,
cardiovascular disease risk factors were significantly lower
in those with better lung function (FEV1) (p<0.001).
Men who were excluded because of missing respira-
tory function values or having either myocardial infarc-
tion, stroke or cancer at baseline (n = 1203) were older
Table 1 Characteristics of 10,168 men and 12,494 women aged 40-79 years without prevalent heart disease, stroke, or cancer, by
quintile of FEV1 in the EPIC-Norfolk, United Kingdom, recruited between 1993-1997
Clinical variables Unit Respiratory function FEV1 category (cL/s) P*
Quintile <229 229 to <272 272 to < 309 309 to < 353 ≥ 353
Men (%, n) 100, 10168 18.3, 1857 19.3, 1959 20.5, 2087 20.6, 2097 21.3, 2168
Mean respiratory function FEV1 (cL/s) 293.7±73.9 184.1± 39.6 252.0±12.1 291.2±10.9 330.7±12.7 392.0±31.5 <0.001
Mean age (year) 58.9±9.3 66.0± 7.9 62.9±8.5 59.3±8.5 56.0±7.8 51.9±6.2 <0.001
Mean Height (cm) 174.2±6.7 170.7±6.5 1712.0±6.2 173.7±6.1 175.5±6.0 178.3±5.8 <0.001
Mean systolic BP (mm Hg) 137.2±17.5 142.8± 19.0 140.8±17.7 137.5±17.8 134.9±15.8 131.1±14.9 <0.001
Mean alcohol (units/week) 10.4±11.9 9.4± 11.9 10.1±12.2 9.9±11.5 11.0±12.1 11.5±11.6 0.411
Mean BMI (kg/m2) 26.5±3.3 26.8± 3.7 27.0±3.3 26.5±3.3 26.3±3.1 26.0±3.1 <0.001
Mean plasma vitamin C (umol/l) 47.4±18.7 42.7± 20.0 45.3±18.2 47.9±18.6 49.1±17.6 51.0±18.2 <0.001
Mean serum cholesterol (mmol/L) 6.0±1.1 6.1±1.1 6.1±1.1 6.1±1.0 6.1±1.1 5.9±1.1 0.897
Physically inactive [% (n)] 29.3(2982) 43.7 (812) 33.2(650) 27.4(571) 24.1(506) 20.4(443) <0.001
Manual social class [% (n)] 41.6(4160) 48.3 (870) 45.6(877) 42.8(877) 38.9(805) 34.1(731) <0.001
No educational qualification [% (n)] 29.5(3001) 44.2 (819) 34.6(678) 29.7(620) 24.9(521) 16.8(363) <0.001
Current smokers [% (n)] 12.5(1261) 17.7 (327) 12.8(249) 13.2(273) 11.6(242) 7.9(170) <0.001
History of diabetes [% (n)] 2.7 (271) 4.0 (74) 4.0(79) 2.6(54) 2.1(45) 0.9(19) <0.001
History of asthma [% (n)] 7.7(787) 17.1 (318) 7.9(154) 6.2(129) 4.9 (102) 3.9(84) <0.001
History of bronchitis [% (n)] 8.7(886) 16.2 (300) 8.1(159) 6.9(143) 6.7(140) 6.6(144) <0.001
Clinical variables Unit Respiratory function FEV1 category (cL/s) P*
Quintile <170 170 to <200 200 to < 227 227 to < 257 ≥ 257
Women (%, n) 100, 12494 19.6, 2449 19.3, 2413 20.2, 2528 20.4, 2555 20.4, 2549
Mean respiratory function FEV1(cL/s) 214.4±52.0 139.9 ± 26.6 186.3±8.7 213.9±7.8 241.7±8.5 285.4±23.0 <0.001
Mean age (year) 58.5±9.3 66.1± 7.7 62.6±8.5 58.4±8.3 54.8±7.4 51.2±6.1 <0.001
Mean Height (cm) 161.0±6.2 157.6±6.0 159.2±5.5 160.8±5.5 162.2±5.5 165.1±5.5 <0.001
Mean systolic BP(mm Hg) 133.6±18.8 142.5± 19.9 137.9±19.3 133.3±17.4 129.5±16.9 125.4±15.6 <0.001
Mean alcohol (units/week) 4.5±5.7 3.7±5.3 3.9±5.1 4.5±5.8 4.9±5.9 5.5±6.1 <0.001
Mean BMI (kg/m2) 26.2±4.3 26.9±4.5 26.8±4.6 26.3±4.3 25.9±4.2 25.1±3.8 <0.001
Mean vitamin C (umol/l) 58.6±19.9 54.5±21.0 57.6±20.3 58.8±19.9 59.9±19.6 61.8±17.8 <0.001
Mean cholesterol (mmol/L) 6.3±1.2 6.7±1.2 6.5±1.2 6.4±1.2 6.2±1.2 5.8±1.1 <0.001
Physical inactive [% (n)] 29.5(3687) 46.3 (1134) 36.1 (871) 26.3 (664) 22.2 (568) 17.7 (450) 0.005
Manual social class [% (n)] 38.9(4738) 44.8 (1045) 42.6 (997) 39.7 (977) 35.6 (893) 32.7 (826) <0.001
No educational qualification [% (n)] 41.7(5205) 58.0 (1419) 49.9 (1204) 42.9 (1083) 34.6 (885) 24.1 (614) <0.001
Current smokers [% (n)] 11.5(1426) 14.1 (341) 12.0 (286) 11.0 (275) 11.3 (287) 9.3 (237) <0.001
History of diabetes [% (n)] 1.4(180) 2.2 (55) 2.1(50) 1.5 (38) 0.9 (23) 0.5 (14) <0.001
History of asthma [% (n)] 9.0(1120) 16.5 (404) 8.7(209) 7.7 (194) 6.4 (164) 5.8 (149) <0.001
History of bronchitis [% (n)] 9.5(1190) 13.9. (340) 9.4 (226) 8.6 (217) 8.3 (212) 7.7 (195) <0.001
*P-value is the association between FEV1 in category with the clinical variables based on ANOVA or chi-square test
†BP blood pressure; BMI, body mass index; SD, standard deviation; FEV1, forced expiratory volume in 1 second; § Weight (kg)/height (m)2
# Self-reported doctor-diagnosed condition
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(65 years vs. 59 years p < 0.001), slightly heavier (BMI
26.9 kg/m2 vs. 26.5 kg/m2 p<0.001) and slightly shorter
(173 cm vs. 174 cm p<0.001) compared to men who
were included in the current analysis. Women who had
been excluded (n = 1253) were older (63 years vs. 59
years p < 0.001) and slightly shorter (160cm vs. 161cm
p<0.001), but there was no difference in BMI (26.4 kg/
m2 vs. 26.2 kg/m2 p = 0.07), when they were compared
to women included in the analysis.
Mortality percentage from 1993 to 2015 and HRs by
FEV1 quintile by cause are shown in Table 2. HRs for
incident total cardiovascular diseases, myocardial infarc-
tion, stroke, and respiratory diseases adjusted first for
age and stratified by sex, and further multivariable ad-
justed as described previously are also shown in Table 2.
There was a strong inverse association between
increasing FEV1 quintiles and total all-cause mortality.
Individuals in the top quintile i.e. those with better
FEV1 had lower risk of mortality (48% in men and 55%
in women) compared to subjects in the bottom quintile.
There appeared to be a significant graded relationship
between fatal and non-fatal cardiovascular (CV) events
across the distribution of FEV1 in both men and women
[men 95% confident interval (CI) (0.73, 0.81) and women
95% CI (0.63, 0.74)]. In men, deaths from cardiovascular
causes, stroke and respiratory diseases were significantly
associated with poorer lung function but this was not
significant for deaths from myocardial infarction. In
women, deaths from cardiovascular causes, myocardial
infarction and respiratory disease were significantly asso-
ciated with lung function but was not significant for
deaths from stroke. Not unexpectedly, the risk of death
due to respiratory illnesses was also significantly associ-
ated with poorer lung function and the hazard ratio was
greater than for CV disease in both men and women.
When analyzed as a continuous variable, for every 70 cL/s
increase in FEV1, there was 28%-35% lower mortality risk
from cardiovascular disease and 68%-72% lower mortality
risk from respiratory disease. These associations were only
slightly attenuated after multivariable adjustment.
In men, unlike the association of FEV1 with stroke
mortality, baseline FEV1 level was not significantly asso-
ciated with stroke incidence but was inversely associated
with incident total cardiovascular disease. In women,
both were significant. A greater magnitude of association
between mortality due to respiratory diseases than CVD
was seen in both men and women.
HRs for total all-cause mortality per increase of 70 cL/
s FEV1, which was similar in the various subgroups
examined, including adjustment by age, smoking status,
BMI, physical activity, social class and plasma vitamin C
are shown in Table 3. This was still apparent after
exclusion of individuals with prevalent respiratory dis-
eases of bronchitis and asthma or individuals who died
within 5 years of follow-up (shown in Table 3). As
shown in Table 3, across the observed range of FEV1
distribution in this cohort, each increase of 70 cL/s was
associated with 23%-32% lower observed mortality risk
in men and women over 18 years. This association was
also consistent in subgroups analysis after adjustment
for age, sex, smoking status, BMI, physical activity, vita-
min C level, and social class.
Discussion
This study demonstrates that in middle-aged and older
men and women, FEV1 was inversely associated with
total mortality. There appears to be a graded relationship
between FEV1 and mortality, with lowest mortality
observed in those with higher FEV1. This inverse associ-
ation was consistent after adjusting for age, BMI, height,
physical activity, smoking, plasma vitamin C concentra-
tions, occupational social class, education, systolic blood
pressure, total cholesterol and diabetes. Our findings are
consistent with findings from other studies [15–20]. The
Renfrew and Paisley prospective population study in
Scotland, [15] reported a significant inverse association
between lower predicted FEV1 and all-cause mortality in
both male and female after adjustment; however, partici-
pants’ height, diabetes status, bronchitis, asthma and
physical activity were unaccounted for. Similarly the
National Health and Nutrition Examination Survey Epi-
demiologic Follow-up Study from 1971 through 1992
and the Buffalo Health study (554 men and 641 women)
from 1960 through 1989 showed that individuals with
the lowest predicted FEV1 had the highest risk of cardio-
vascular death [18].
Not unexpectedly in our study, more subjects with
lower FEV1 had asthma and bronchitis. The underlying
pathology in asthma and bronchitis is endothelial patho-
geny and persistent low-grade bronchial inflammation
which has been proposed to be responsible for endothe-
lium dysfunction and atherosclerosis, and subsequently
contribute to fatal cardiovascular disease [20–25]. Smok-
ing also has a direct effect on the development of pul-
monary hypertension which in turn increases mortality
and morbidity from cardiovascular related disease [26].
Patients with poorer lung function are prone to get re-
spiratory infections due to impaired mechanism in local
defence system and most of them are expected to die
from respiratory failure if they have frequent acute exac-
erbations [27–29].
Our study shows that lung function in men is not as-
sociated with fatal myocardial infarction (MI). A possible
reason is that cholesterol concentration, a risk factor
which has the greatest impact on causing MI [30, 31] is
the same across the quintiles of FEV1 in men. In other
words, men have an equal chance of dying from myocar-
dial infarction when they have similar cholesterol levels
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Table 2 Hazard ratios by FEV category for mortality by cause and incidence for cardiovascular disease and respiratory disease in
22662 men and women in the EPIC-Norfolk 1993-2015
Respiratory function FEV1 category (cL/s)
Quintile <229 229 to <272 272 to < 309 309 to < 353 ≥ 353 HR(95% CI) per
70 cL/s increase
P-linear
trend
Men
Deaths: all causes % (n) 35.8
(1108)
25.7 (794) 18.7 (579) 12.7 (394) 7.1 (221) <0.001
HR (95% CI) a 1 0.69(0.63,0.75) 0.60(0.54,0.66) 0.55(0.49,0.62) 0.48(0.41,0.56) 0.72(0.69,0.75) <0.001
HR (95% CI) b 1 0.74(0.67,0.82) 0.69(0.61.77) 0.66(0.58,0.76) 0.63(0.52,0.76) 0.77(0.73,0.81) <0.001
Deaths from cardiovascular
causes % (n)
37.5
(359)
29.2 (279) 16.3 (156) 12.1 (116) 4.9 (47) <0.001
HR (95% CI) a 1 0.77(0.66,0.9) 0.54(0.44,0.65) 0.57(0.46,0.72) 0.39(0.28,0.54) 0.70(0.65,0.76) <0.001
HR (95% CI) b 1 0.89(0.75,1.06) 0.67(0.54,0.84) 0.75(0.58,0.97) 0.64(0.44,0.92) 0.80(0.73,0.88) <0.001
Deaths from myocardial infarction
causes % (n)
35.1
(191)
29.5 (161) 15.2 (83) 14.1 (77) 6.1 (33) <0.001
HR (95% CI) a 1 0.84(0.68,1.04) 0.54(0.41,0.70) 0.71(0.53,0.94) 0.50(0.33,0.75) 0.75(0.68,0.83) <0.001
HR (95% CI) b 1 0.99(0.78,1.26) 0.70(0.52,0.94) 0.97(0.70,1.35) 0.90(0.57,1.42) 0.88(0.78,1.00) 0.05
Deaths from stroke causes % (n) 33.7 (
68)
31.7 (64) 19.8 (40) 12.3 (25) 2.5 (5) <0.001
HR (95% CI) a 1 0.91(0.65,1.28) 0.72(0.48,1.08) 0.66(0.41,1.08) 0.24(0.09,0.61) 0.73(0.62,0.86) 0.027
HR (95% CI) b 1 0.97(0.66,1.42) 0.78(0.49,1.23) 0.78(0.45,1.37) 0.38(0.14,1.04) 0.78(0.64,0.95) 0.015
Deaths from respiratory disease
causes %(n)
62.4
(184)
17.6 (52) 12.5 (37) 5.1 (15) 2.4 (7) <0.001
HR (95% CI) a 1 0.27(0.20,0.37) 0.24(0.17,0.35) 0.14(0.08,0.25) 0.12(0.05,0.26) 0.32(0.28,0.36) <0.001
HR (95% CI) b 1 0.33(0.23,0.46) 0.29(0.19,0.43) 0.20(0.11,0.35) 0.19(0.08,0.43) 0.35(0.30,0.41) <0.001
Cardiovascular disease events %(n) 28.5
(1028)
23.9 (863) 21.1 (760) 15.9 (576) 10.6 (384) <0.001
HR (95% CI) a 1 0.78(0.71,0.85) 0.73(0.66,0.80) 0.64(0.57,0.71) 0.51(0.45,0.58) 0.80(0.77,0.83) <0.001
HR (95% CI) b 1 0.82(0.74,0.91) 0.81(0.72,0.90) 0.73(0.64,0.82) 0.63(0.54,0.73) 0.85(0.81,0.89) <0.001
Myocardial infarction events % (n) 30.6(528) 25.0(431) 19.7 (340) 15.9 (275) 8.8 (152) <0.001
HR (95% CI) a 1 0.78(0.69,0.89) 0.66(0.58,0.76) 0.63(0.54,0.74) 0.42(0.34,0.51) 0.77(0.73,0.81) <0.001
HR (95% CI) b 1 0.85(0.74,0.98) 0.78(0.67,0.91) 0.79(0.66,0.95) 0.58(0.46,0.73) 0.85(0.79,0.91) 0.001
Stroke events % (n) 34.7
(157)
28.0 (127) 16.8 (76) 12.8 (58) 7.7 (35) <0.001
HR (95% CI) a 1 0.86(0.68,1.08) 0.62(0.47,0.82) 0.66(0.48,0.92) 0.64(0.43,0.97) 0.79(0.71,0.88) 0.008
HR (95% CI) b 1 0.98(0.75.1.28) 0.78(0.57,1.08) 0.86(0.59,1.26) 0.99(0.96,1.02) 0.90(0.79,1.03) 0.13
Respiratory disease events %(n) 41.3
(669)
22.0 (357) 16.7 (271) 11.5 (186) 8.5 (138) <0.001
HR (95% CI) a 1 0.46(0.40,0.52) 0.34(0.29,0.39) 0.25(0.21,0.30) 0.21(0.17,0.26) 0.51(0.48,0.54) <0.001
HR (95% CI) b 1 0.48(0.41,0.55) 0.37(0.32,0.44) 0.28(0.23,0.33) 0.26(0.18,0.28) 0.52(0.49,0.55) <0.001
Respiratory function FEV1 category (cL/s)
Quintile <170 170 to <200 200 to < 227 227 to < 257 ≥ 257 HR(95%CI) per 70 cL/s
increase
P-linear
trend
Women
Deaths: all causes % (n),2758 42.1
(1161)
25.0 (688) 16.6 (459) 9.6 (266) 6.7 (184) <0.001
HR (95% CI) a 1 0.68(0.63,0.75) 0.62(0.55,0.69) 0.51(0.44,0.59) 0.55(0.46,0.66) 0.65(0.61,0.69) <0.001
HR (95% CI) b 1 0.71(0.64,0.80) 0.65(0.57,0.74) 0.57(0.48,0.67) 0.62(0.51,0.76) 0.68(0.63,0.74) <0.001
Deaths from cardiovascular
causes % (n)
47.1(376) 27.7 (221) 16.5 (132) 5.9 (47) 2.8 (22) <0.001
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regardless of their lung function. And hence fatal myo-
cardial infarction is not significant with the FEV1 distri-
bution among men in our study.
The difference in systolic BP in men across the quin-
tiles was smaller than for women (131-143mmHg versus
125-143mmHg). As strokes are very BP dependent [32,
33] and because of this smaller difference in BP, the
stroke risk is not significantly different across the quin-
tiles. However, FEV1 has an inverse relationship in
stroke related death in men but not in women, a pos-
sible explanation for which might be the fact that
women in this study have a higher vitamin C consump-
tion (59 μmol/L versus 47 μmol/L), which works as a
protective mechanism to reduce fatal stroke as our
earlier observations on plasma vitamin C was inversely
associated with the risk of atrial fibrillation in women
but not men [34].
Lower FEV1 may be a marker of smoking but our
study demonstrated that after adjusting for smoking sta-
tus, lower FEV1 was significantly associated with in-
creased total mortality among smokers, former smokers
and never smokers. This finding is similar to the
Copenhagen City Heart Study in Denmark [35]. Even
though this study shows that there is an association
between FEV1 and total cardiovascular mortality and
morbidity, we should not interpret the results in terms
of causality in the absence of complete causal directional
acyclic graphs or conceptual framework. However, it
Table 2 Hazard ratios by FEV category for mortality by cause and incidence for cardiovascular disease and respiratory disease in
22662 men and women in the EPIC-Norfolk 1993-2015 (Continued)
Respiratory function FEV1 category (cL/s)
Quintile <229 229 to <272 272 to < 309 309 to < 353 ≥ 353 HR(95% CI) per
70 cL/s increase
P-linear
trend
HR (95% CI) a 1 0.73(0.61,0.86) 0.67(0.55,0.82) 0.39(0.29,0.54) 0.35(0.22,0.55) 0.65(0.57,0.73) <0.001
HR (95% CI) b 1 0.76(0.63,0.92) 0.73(0.57,0.92) 0.50(0.36,0.71) 0.40(0.24,0.67) 0.67(0.58,0.78) <0.001
Deaths from myocardial infarction
causes %(n)
48.3
(146)
27.2 (82) 16.9 (51) 5.6 (17) 2.0(6) <0.001
HR (95% CI) a 1 0.69(0.52,0.89) 0.63(0.45,0.88) 0.33(0.20,0.56) 0.21(0.09,0.49) 0.56(0.46,0.67) <0.001
HR (95% CI) b 1 0.77(0.57,1.04) 0.67(0.45,0.99) 0.46(0.26,0.81) 0.27(0.10,0.72) 0.60(0.47,0.75) <0.001
Deaths from stroke causes %(n) 43.5
(133)
30.4 (93) 16.7 (51) 6.5 (20) 2.9 (9) <0.001
HR (95% CI) a 1 0.88(0.68,1.15) 0.79(0.57,1.11) 0.54(0.33,0.89) 0.51(0.25,1.04) 0.81(0.67,0.99) 0.08
HR (95% CI) b 1 0.89(0.65,1.21) 0.86(0.59,1.27) 0.66(0.39,1.13) 0.55(0.25,1.21) 0.85(0.67,1.08) 0.18
Deaths from respiratory disease
causes %(n)
61.1
(149)
20.9(51) 11.0 (27) 4.9 (12) 2.1 (5) <0.001
HR (95% CI) a 1 0.39(0.28,0.54) 0.29(0.19,0.44) 0.19(0.10,0.35) 0.13(0.05,0.33) 0.28(0.23,0.35) <0.001
HR (95% CI) b 1 0.43(0.30,0.62) 0.39(0.25,0.62) 0.26(0.13,0.51) 0.24(0.09,0.63) 0.35(0.27,0.44) <0.001
Cardiovascular disease events %(n) 33.8
(1206)
25.9 (924) 18.6 (664) 12.6 (446) 9.1 (325) <0.001
HR (95% CI) a 1 0.83(0.76,0.91) 0.68(0.62,0.75) 0.54(0.48,0.61) 0.50(0.43,0.57) 0.72(0.68,0.76) <0.001
HR (95% CI) b 1 0.85(0.77,0.94) 0.75(0.67,0.84) 0.64(0.56,0.73) 0.58(0.49,0.68) 0.77(0.72,0.83) <0.001
Myocardial infarction events %(n) 39.7
(429)
26.9(291) 17.8 (192) 8.8 (95) 6.8 (74) <0.001
HR (95% CI) a 1 0.79(0.68,0.92) 0.67(0.56,0.80) 0.43(0.34,0.54) 0.47(0.35,0.62) 0.69(0.63,0.76) <0.001
HR (95% CI) b 1 0.79(0.67,0.94) 0.70(0.57,0.85) 0.48(0.37,0.63) 0.59(0.43,0.81) 0.74(0.66,0.83) <0.001
Stroke events %(n) 46.7
(233)
25.9 (129) 15.4 (77) 7.4 (37) 4.6 (23) <0.001
HR (95% CI) a 1 0.69(0.56,0.86) 0.62(0.47,0.81) 0.46(0.31,0.66) 0.47(0.29,0.76) 0.71(0.61,0.82) <0.001
HR (95% CI) b 1 0.68(0.53,0.88) 0.67(0.49,0.91) 0.51(0.34,0.77) 0.48(0.28,0.83) 0.74(0.62,0.89) 0.001
Respiratory disease events %(n) 40.3
(665)
23.1 (382) 16.2 (268) 11.9 (196) 8.5 (141) <0.001
HR (95% CI) a 1 0.55(0.41,0.63) 0.39(0.38,0.46) 0.30(0.25,0.36) 0.23(0.19,0.28) 0.43(0.40,0.47) <0.001
HR (95% CI) b 1 0.54(0.47,0.62) 0.40(0.34,0.47) 0.29(0.24,0.36) 0.21(0.16,0.26) 0.42(0.38,0.46) <0.001
aModel 1: adjusting for age
bModel 2: adjustment for BMI, cigarette-smoking habit, alcohol intake, physical activity, height, education level, plasma vitamin C, social class, self-reported
diabetes, respiratory disease, systolic blood pressure and plasma total cholesterol
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may be considered as another surrogate marker for car-
diovascular risk.
Strength and limitation
Our present study has several strengths and some limita-
tions. The strength of our study is that it was done in
the community where the findings reflect more that of
the general population at large. Secondly, our sample
size is large enough to investigate the relationship in
subjects who were lifelong non-smokers, free of cancer,
myocardial infarction and stroke at the outset of the
study. This gives a more robust picture of the relation-
ship between lung function and total mortality and mor-
bidity in a general population who are at a lower risk of
cardiovascular disease. The Whitehall II study in United
Kingdom, in a subset of 4,817 participants who had lung
function measured showed similar findings. However,
their sample size was relatively small and the follow-up
was much shorter at 6.4 years [20]. A further strength of
our study was that mortality presented using gender
stratification and included adjustments for
socio-economic factors and physical inactivity. Previous
studies also showed a similar relationship between FEV1
and cardiovascular mortality and morbidity [36, 37]. Our
study provides a more contemporary setting for this
relationship while also reaffirming previous findings.
The results of this study should be interpreted in the
context of its limitations. Firstly, the gold standard for
measurement of FEV1 with spirometry was not used in
this study. Although a handheld spirometer has good
sensitivity and specificity in identifying COPD when
compared with the gold standard spirometry, the accur-
acy of this tool for discriminating non-obstructive pul-
monary abnormalities has not been established [38].
Furthermore, it may overestimate the prevalence of
COPD as the cut-off point of FEV1/FVC for a handheld
Table 3 Cox multivariate-adjusted HRs for all-cause mortality in the EPIC-Norfolk 1993-2015 per 70cL/s increase in FEV1 in
subgroups adjusted by age and other covariates
Number/ Total HR (95%CI) per 70 cL/s increase in FEV1 a P HR (95%CI) per 70 cL/s increase in FEV1 b P
All 4734/19139 0.71(0.68, 0.73) <0.001 0.74(0.71, 0.77) <0.001
Gender
Men 2572/8719 0.72(0.69, 0.76) <0.001 0.77(0.73, 0.81) <0.001
Women 2162/8258 0.67(0.62, 0.72) <0.001 0.68(0.63, 0.74) <0.001
Age
<65 1661/13631 0.74(0.70, 0.78) <0.001 0.79(0.74, 0.84) <0.001
≥65 3073/5508 0.67(0.65, 0.71) <0.001 0.70(0.67, 0.74) <0.001
Excluding early deaths < 5 years 4196/18601 0.72(0.69, 0.75) <0.001 0.76(0.72, 0.79) <0.001
Smoking status
-Current smokers 670/ 2214 0.72(0.65, 0.80) <0.001 0.71(0.63, 0.79) <0.001
-Ex-smokers 2344/7955 0.71(0.67, 0.75) <0.001 0.72(0.68, 0.76) <0.001
-Never smokers 1720/8970 0.81(0.75, 0.87) <0.001 0.82(0.76, 0.89) <0.001
By BMI
<27 kg/m2 2759/12146 0.69(0.66, 0.73) <0.001 0.73(0.69, 0.77) <0.001
≥27 kg/m2 1975/6993 0.72(0.69, 0.78) <0.001 0.75(0.71, 0.81) <0.001
By physical activity
- Inactive 1977/5467 0.65(0.62, 0.69) <0.001 0.68(0.64, 0.72) <0.001
- Active 2757/13672 0.76(0.72, 0.80) <0.001 0.79(0.75, 0.84) <0.001
Excluding asthma or bronchitis 4772/17837 0.72(0.69, 0.75) <0.001 0.76(0.73, 0.79) <0.001
Social class
-Nonmanual social class 2737/11509 0.73(0.69, 0.77) <0.001 0.75(0.71, 0.80) <0.001
-Manual social class 1997/7630 0.69(0.65, 0.73) <0.001 0.72(0.68, 0.77) <0.001
Plasma Vitamin C
-Less than median 2646/9206 0.71(0.67, 0.75) <0.001 0.73(0.69, 0.77) <0.001
-more than median 2088/9933 0.74(0.69, 0.78) <0.001 0.75(0.71, 0.80) <0.001
Foot note: a Model 1: adjusting for age
bModel 2: adjustment for BMI, cigarette-smoking habit, alcohol intake, physical activity, height, education level, plasma vitamin C, social class, self-reported
diabetes, respiratory disease, systolic blood pressure and plasma total cholesterol
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spirometry is higher compared with the FEV1/FVC ratio
used in the gold standard spirometry [39]. Secondly, two
instead of three FEV1 measurements were taken in the
study. However, in view that this study is a large-scale
community-based survey, it was not practical to perform
three measurements or the gold standard spirometry
test. Despite this limitation, the results of this study can
still provide health care professionals with some insights
on the association between the FEV1 and total cardio-
vascular mortality and morbidity. The findings in this
study has shown that a portable handheld device can
serve as a screening tool to identify those with abnormal
results for a further formal assessment in a specialised
centre. Thirdly, there was some missing data (n=596) on
the FEV1 but this only represented 2% of the total popu-
lation and did not affect our findings in any substantial
way. Thus, the implication of the current study was that
the portable handheld device can serve as a screening
tool to screen for those at risk of having cardiovascular
or respiratory morbidity.
Conclusions
A lower FEV1 is an independent risk factor for all-cause
and cardiovascular mortality and morbidity among men
and women. In addition to the recommended BP, blood
glucose and lipids measurements during routine clinical
consultation or during healthcare screening, measuring
the FEV1 with a portable handheld spirometry may be
used as a surrogate marker for cardiovascular risk. Every
effort should be made to identify those with poorer lung
function even in the absence of cardiovascular disease as
they are at greater risk of total and CV mortality
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